Anti-Aβ antibody target engagement: a response to Siemers et al

Andrew D Watt, Gabriela A N Crespi, Russell A Down, David B Ascher, Adam Gunn, Keyla A Perez, Catriona A McLean, Victor L Villemagne, Michael W Parker, Kevin J Barnham, Luke A Miles

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.
Original languageEnglish
Pages (from-to)611-4
Number of pages4
JournalActa Neuropathologica
Volume128
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint Dive into the research topics of 'Anti-Aβ antibody target engagement: a response to Siemers et al'. Together they form a unique fingerprint.

  • Cite this

    Watt, A. D., Crespi, G. A. N., Down, R. A., Ascher, D. B., Gunn, A., Perez, K. A., McLean, C. A., Villemagne, V. L., Parker, M. W., Barnham, K. J., & Miles, L. A. (2014). Anti-Aβ antibody target engagement: a response to Siemers et al. Acta Neuropathologica, 128(4), 611-4. https://doi.org/10.1007/s00401-014-1333-8